Harnessing the Power of ADCs

Our technologies

P5 Conjugation​

The Next Generation Conjugation for High DAR ADCs

Our P5 Conjugation Technology allows to rapidly generate ultra-stable ADCs with antibody-like biophysical properties and chemical flexibility providing us with the opportunity to develop truly differentiated ADCs

More about P5

Tubutecan

Driving Superior Topo1 ADCs

Leveraging the P5 technology, our proprietary Tubutecan Platform enables stable, high DAR 8 conjugation of potent topoisomerase-I inhibitors with optimized on-target delivery and reduced off-target toxicity – without compromising ADC properties.

More about Tubutecan

Same Linker-Payload – Different Antibody

TUB-040
NaPi2b
TUB-030​
5T4
TUB-050
TUB-060
Our Pipeline

The New Generation of ADCs

Alco5

Unlocking Next Gen Payloads

Our Alco5 Platform enables stable antibody conjugation of previously inaccessible payload classes, including various cytotoxins and protein degraders – unlocking novel MoAs while preserving favorable ADC properties properties.

More about Alco5

Novel Antibody and Payload Combinations

Novel Payload 
Classes
Degrader Antibody Conjugates

Next generation Cystein conjugation chemistry/platform.

Simple incorporation of the P5 handle followed by an extremely efficient, highly reproducible antibody conjugation process yields homogenous  and hydrophilic high DAR ADCs.

P5 enables superior linker stability in serum compared to standard maleimide-based linker systems.

P5 prevents undesired Linker-Payload transfer to endogenous serum proteins. A mechanism known for standard maleimide-based linker systems.